StockMacro
Company, fund or insider

Help

Menu

AnaptysBio

$46.63 -19% in 6 monthsMarket cap $1.4B

ANAB on XNAS, Health Care, AnaptysBio, Inc., job postings

Measures activity, not value. Not investment advice.

Latest quarter revenue fell 60% to $30.3M while insiders bought $17.2M and short interest is 17%.

  • WatchLast 12 months revenue still rose 13% to $191.6M
  • GoodInstitutional holders rose 7.6% to 226 filers from 210

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Industry
Pharmaceutical preparations (Health Care)
Employees
104
Website
anaptysbio.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 8 Jan 2027 (an estimate: a year ago it reported on 9 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $30.3M, net income $3.9M.
Quarter to 31 Dec 2021: revenue –, net income -$32.5MQuarter to 31 Mar 2022: revenue $970K, net income -$36.3MQuarter to 31 Mar 2022: revenue $970K, net income -$36.3MQuarter to 30 Jun 2022: revenue $1.2M, net income -$32.6MQuarter to 30 Jun 2022: revenue $1.2M, net income -$32.6MQuarter to 30 Sep 2022: revenue $1.3M, net income -$33.5MQuarter to 30 Sep 2022: revenue $1.3M, net income -$33.5MQuarter to 31 Dec 2022: revenue –, net income -$26.4MQuarter to 31 Mar 2023: revenue $1.4M, net income -$44.3MQuarter to 31 Mar 2023: revenue $1.4M, net income -$44.3MQuarter to 30 Jun 2023: revenue $3.5M, net income -$39.8MQuarter to 30 Jun 2023: revenue $3.5M, net income -$39.8MQuarter to 30 Sep 2023: revenue $3.3M, net income -$37.3MQuarter to 30 Sep 2023: revenue $3.3M, net income -$37.3MQuarter to 31 Dec 2023: revenue $9.0M, net income -$42.2MQuarter to 31 Dec 2023: revenue $9.0M, net income -$42.2MQuarter to 31 Mar 2024: revenue $7.2M, net income -$43.9MQuarter to 31 Mar 2024: revenue $7.2M, net income -$43.9MQuarter to 30 Jun 2024: revenue $11.0M, net income -$46.7MQuarter to 30 Jun 2024: revenue $11.0M, net income -$46.7MQuarter to 30 Sep 2024: revenue $30.0M, net income -$32.9MQuarter to 30 Sep 2024: revenue $30.0M, net income -$32.9MQuarter to 31 Dec 2024: revenue $43.1M, net income -$21.8MQuarter to 31 Dec 2024: revenue $43.1M, net income -$21.8MQuarter to 31 Mar 2025: revenue $27.8M, net income -$39.3MQuarter to 31 Mar 2025: revenue $27.8M, net income -$39.3MQuarter to 30 Jun 2025: revenue $22.3M, net income -$38.6MQuarter to 30 Jun 2025: revenue $22.3M, net income -$38.6MQuarter to 30 Sep 2025: revenue $76.3M, net income $15.1MQuarter to 30 Sep 2025: revenue $76.3M, net income $15.1MQuarter to 31 Dec 2025: revenue $108.2M, net income $49.6MQuarter to 31 Dec 2025: revenue $108.2M, net income $49.6MQuarter to 31 Mar 2026: revenue $25.6M, net income -$52.9MQuarter to 31 Mar 2026: revenue $25.6M, net income -$52.9MQuarter to 30 Jun 2026: revenue $27.5M, net income $183.9MQuarter to 30 Jun 2026: revenue $27.5M, net income $183.9MQuarter to 30 Sep 2026: revenue $30.3M, net income $3.9MQuarter to 30 Sep 2026: revenue $30.3M, net income $3.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $183.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$30.3M$3.9M
30 Jun 2026$27.5M$183.9M
31 Mar 2026$25.6M-$52.9M
31 Dec 2025$108.2M$49.6M
30 Sep 2025$76.3M$15.1M
30 Jun 2025$22.3M-$38.6M
31 Mar 2025$27.8M-$39.3M
31 Dec 2024$43.1M-$21.8M
30 Sep 2024$30.0M-$32.9M
30 Jun 2024$11.0M-$46.7M
31 Mar 2024$7.2M-$43.9M
31 Dec 2023$9.0M-$42.2M
30 Sep 2023$3.3M-$37.3M
30 Jun 2023$3.5M-$39.8M
31 Mar 2023$1.4M-$44.3M
31 Dec 2022–-$26.4M
30 Sep 2022$1.3M-$33.5M
30 Jun 2022$1.2M-$32.6M
31 Mar 2022$970K-$36.3M
31 Dec 2021–-$32.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $191.6M $169.5M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $184.5M -$84.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – 8.2% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 96.3% -49.9% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$145.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $153.0M $249.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$153.0M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.70
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 7.5 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.2 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.4 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 66.6 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
AnaptysBioANAB (this company) $1.4B7.57.2+13%96.3%
Tyra BiosciencesTYRA $1.4Bloss–––
Rapport TherapeuticsRAPP $1.4Bloss–––
Nurix TherapeuticsNRIX $1.4B4.82.0+739%42.0%
uniQureQURE $1.4Bloss67.3+28%–
UroGen PharmaURGN $1.4Bloss5.4+159%-26.3%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-60%

$30.3M vs $76.3M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$17.0M

bought $17.2M, sold $249K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+7.6%

226 13F filers vs 210

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

30.8M shares held by 13F filers (30 Sep 2026) of 29.7M outstanding (9 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

17%

5.1M shares sold short (30 Oct 2026) of 29.7M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.8

5.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.3%

5.4M shares sold short in the report before, 5.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

21

21 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

21×

21 articles in the last 7 days; its usual week has 1.

Price $46.63 on 20 Nov 2026, +24% over 12 months (12-month range $37.66 to $70.22)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $7.5M in the last 12 months (the 12 months before: -$155K).
Revenue per quarter. Revenue $30.3M in the latest quarter, -60% on a year earlier.
Capital spending per quarter. Capital spending $17K in the latest quarter, -51% on a year earlier.
Institutional holders (13F filers). 226 13F filers reported holding it in the latest 13F quarter, +44% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
11 May 20268-K and other filingsDirector or officer change
20 Apr 20268-K and other filingsDirector or officer change
20 Apr 20268-K and other filingsCompleted an acquisition or asset sale
27 Mar 20268-K and other filingsDirector or officer change
27 Mar 20268-K and other filingsA major agreement ended
27 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 108.2M vs usual 25.0M (2025-12-31); 2.5x the same period a year earlier
6 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 76.3M vs usual 16.6M (2025-09-30); 2.5x the same period a year earlier
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 43 vs usual 14.50 (2025-03-31); 1.9x the same period a year earlier
4 Mar 2025Sharp changeQuarterly revenue change: quarterly revenue change, 43.1M vs usual 5.3M (2024-12-31); 4.8x the same period a year earlier
17 Dec 2024Sharp changeShort interest spike: short interest spike, 7.1M vs usual 4.7M (2024-11-29); 1.4x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 32 vs usual 12.50 (2024-09-30); 3.2x the same period a year earlier
12 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 30.0M vs usual 3.4M (2024-09-30); 9.0x the same period a year earlier
6 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 11.0M vs usual 2.3M (2024-06-30); 3.2x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 23 vs usual 12.50 (2024-03-31); 1.8x the same period a year earlier
18 Sep 20238-K and other filingsDirector or officer change
18 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Apr 20238-K and other filingsDirector or officer change
6 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Nov 2022Sharp changeShort interest spike: short interest spike, 5.5M vs usual 2.7M (2022-10-14); 2.2x the same period a year earlier
18 Oct 2022Sharp changeShort interest spike: short interest spike, 5.6M vs usual 2.7M (2022-09-30); 2.2x the same period a year earlier
27 Sep 2022Sharp changeShort interest spike: short interest spike, 5.4M vs usual 2.7M (2022-09-15); 1.9x the same period a year earlier
13 Sep 2022Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.7M (2022-08-31); 1.8x the same period a year earlier
30 Aug 2022Sharp changeShort interest spike: short interest spike, 4.4M vs usual 2.7M (2022-08-15); 1.5x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 4.5M vs usual 2.7M (2022-07-29); 1.5x the same period a year earlier
29 Apr 20228-K and other filingsDirector or officer change
21 Mar 20228-K and other filingsDirector or officer change
21 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Dec 20218-K and other filingsCompleted an acquisition or asset sale
29 Nov 20218-K and other filingsDirector or officer change
29 Nov 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$1.3M published
Month from 1 May 2022: -$23K published
Month from 1 Jun 2022: -$60K published
Month from 1 Aug 2022: -$13K published
Month from 1 Sep 2023: -$274K published
Month from 1 Nov 2023: -$13K published
Month from 1 Jan 2024: -$303K published
Month from 1 Feb 2024: -$197K published
Month from 1 Mar 2024: -$3.4M published
Month from 1 May 2024: -$36K published
Month from 1 Jun 2024: -$90K published
Month from 1 Jul 2024: -$359K published
Month from 1 Aug 2024: $9.9M published
Month from 1 Sep 2024: -$1.1M published
Month from 1 Dec 2024: -$250K published
Month from 1 Jan 2025: $1.1M published
Month from 1 Jun 2025: -$72K published
Month from 1 Jul 2025: -$493K published
Month from 1 Aug 2025: -$201K published
Month from 1 Oct 2025: -$239K published
Month from 1 Dec 2025: -$3.0M published
Month from 1 Jan 2026: -$3.7M published
Month from 1 Feb 2026: -$540K published
Month from 1 Mar 2026: -$1.1M published
Month from 1 Apr 2026: -$1.2M published
Month from 1 Oct 2026: -$249K published
Month from 1 Nov 2026: $17.2M published
Revenue per quarter
Quarter ended 31 Mar 2022: $970K, -91% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $1.2M, -96% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $1.3M, -94% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Mar 2023: $1.4M, +42% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $3.5M, +185% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $3.3M, +157% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $9.0M; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $7.2M, +422% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $11.0M, +217% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $30.0M, +805% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $43.1M, +379% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $27.8M, +287% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $22.3M, +103% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $76.3M, +154% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $108.2M, +151% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $25.6M, -8.0% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $27.5M, +23% on a year earlier; public on 22 Sep 2026
Quarter ended 30 Sep 2026: $30.3M, -60% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $55K, -83% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $78K, -91% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $50K, -71% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $175K; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $175K, +218% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $190K, +144% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $162K, +224% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $280K, +60% on a year earlier; public on 12 Mar 2024
Quarter ended 31 Mar 2024: $27K, -85% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $33K, -83% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $35K, -78% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $263K, -6.1% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $35K, +30% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $39K, +18% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $12K, -66% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $17K, -51% on a year earlier; public on 13 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 128; public on 14 Feb 2022
31 Mar 2022 report: 128; public on 16 May 2022
30 Jun 2022 report: 119; public on 15 Aug 2022
30 Sep 2022 report: 108; public on 14 Nov 2022
31 Dec 2022 report: 110; public on 14 Feb 2023
31 Mar 2023 report: 108; public on 15 May 2023
30 Jun 2023 report: 109; public on 14 Aug 2023
30 Sep 2023 report: 110; public on 14 Nov 2023
31 Dec 2023 report: 113; public on 14 Feb 2024
31 Mar 2024 report: 128; public on 15 May 2024
30 Jun 2024 report: 126; public on 14 Aug 2024
30 Sep 2024 report: 155; public on 14 Nov 2024
31 Dec 2024 report: 133; public on 14 Feb 2025
31 Mar 2025 report: 152; public on 15 May 2025
30 Jun 2025 report: 142; public on 14 Aug 2025
30 Sep 2025 report: 157; public on 14 Nov 2025
31 Dec 2025 report: 174; public on 17 Feb 2026
31 Mar 2026 report: 199; public on 15 May 2026
30 Jun 2026 report: 210; public on 14 Aug 2026
30 Sep 2026 report: 226; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $17.2M (18 Nov 2026), higher than 98% of its own history.
  • Insider net buying (open market): Insiders bought a net $7.5M in the last 12 months (the 12 months before: -$155K).
  • Revenue per quarter: Revenue $30.3M in the latest quarter, -60% on a year earlier.
  • Capital spending per quarter: Capital spending $17K in the latest quarter, -51% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 88 insider trades

Last 90 days: 1 sale, $249K; 1 purchase, $17.2M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026EcoR1 Capital, LLC and 1 otherDirector, 10% ownerBuy374,580$45.98$17.2MForm 4
2 Oct 2026Hollings RentonDirectorSellplanned in advance (10b5-1); after exercising options5,000$49.87$249KForm 4
1 Apr 2026John P. SchmidDirectorSell20,645$56.11$1.2MForm 4
27 Mar 2026Daniel FagaPresident, CEOSell17,679$61.61$1.1MForm 4
13 Feb 2026Eric J LoumeauCHIEF LEGAL OFFICERSellplanned in advance (10b5-1); after exercising options10,000$54.00$540KForm 4
16 Jan 2026Magda MarquetDirectorSellafter exercising options11,000$48.23$531KForm 4
9 Jan 2026Eric J LoumeauCHIEF LEGAL OFFICERSellafter exercising options2,210$44.71$99KForm 4
9 Jan 2026Paul F. LizzulChief Medical OfficerSellafter exercising options3,650$44.71$163KForm 4

226 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 48 opened a position, 33 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
EcoR1 Capital, LLC7.9M26.5%$396.1MNo change
BlackRock, Inc.1.9M6.36%$95.1M+47K+2.6%
Tang Capital Management LLC1.5M4.96%$74.1M+143K+11%
State Street Corp1.1M3.85%$57.6M-140K-11%
Vanguard Capital Management LLC910K3.06%$45.7M+3,713+0.4%
Goldman Sachs Group Inc850K2.86%$42.7M+266K+46%
Sanofi822K2.76%$41.3MNo change
D. E. Shaw & Co., Inc.820K2.76%$41.2M+280K+52%
Millennium Management LLC785K2.64%$39.4M-23K-2.8%
683 Capital Management, LLC740K2.49%$37.2M+80K+12%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 17 Jun 2010. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
17 Jun 2010Department of the InteriorDepartmental OfficesANTIBODY TECHNOLOGY PROGROMUSAspending

Company events

All 45 company events

In 12 months: 3 major agreements, 3 director or officer changes, 1 agreement ended, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
22 Jun 2026Signed a major agreement8-K
11 May 2026Director or officer change8-K
20 Apr 2026Director or officer change; Signed a major agreement; Completed an acquisition or asset sale8-K
27 Mar 2026Director or officer change; Signed a major agreement; A major agreement ended8-K
3 Feb 2025Signed a major agreement8-K
14 Aug 2024Signed a major agreement8-K
27 Nov 2023Signed a major agreement8-K
18 Sep 2023Director or officer change8-K

The 5 newest of 127 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 Nov 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

AnaptysBio (ANAB): reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year; it also saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year; and it had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year. Three unrelated kinds of activity within 35 days.

  • Financials: Quarterly revenue change, became public on 12 Nov 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
  • Short interest and volume: Short interest spike, became public on 11 Dec 2024
2022-06-30: $1.2M2022-09-30: $1.3M2023-03-31: $1.4M2023-06-30: $3.5M2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M
The quarter ended 30 Sep 2024 against the 8 quarters before it. this quarterearliernormal: $3.4M
See the evidence (3 changes)

Financials: Quarterly revenue change became public on 12 Nov 2024

AnaptysBio reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year.

This period
$30.0M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$3.4M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+8.4
Same quarter last year
$3.3M
History used
3,105 days
2022-06-30: $1.2M2022-09-30: $1.3M2023-03-31: $1.4M2023-06-30: $3.5M2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M
the quarter ended 30 Sep 20248 earlier quartersnormal: $3.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

AnaptysBio saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year.

This period
32 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
12.5
Typical spread (median absolute deviation)
2
How far from its usual level
+6.5
Same quarter last year
10
History used
2,740 days
2022-09-30: 112022-12-31: 102023-03-31: 132023-06-30: 132023-09-30: 102023-12-31: 122024-03-31: 232024-06-30: 222024-09-30: 32
the quarter ended 30 Sep 20248 earlier quartersnormal: 12.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Dec 2024

AnaptysBio had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year.

This period
7.1M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
4.7M
Typical spread (median absolute deviation)
436K
How far from its usual level
+3.7
Same report last year
5.0M
History used
2,527 days
2023-11-30: 5.0M2023-12-15: 4.5M2023-12-29: 4.5M2024-01-12: 4.5M2024-01-31: 5.1M2024-02-15: 4.5M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 4.3M2024-04-15: 4.3M2024-04-30: 4.4M2024-05-15: 4.4M2024-05-31: 4.5M2024-06-14: 4.6M2024-06-28: 4.9M2024-07-15: 5.2M2024-07-31: 5.7M2024-08-15: 5.6M2024-08-30: 5.6M2024-09-13: 5.8M2024-09-30: 6.0M2024-10-15: 6.0M2024-10-31: 6.2M2024-11-15: 6.7M2024-11-29: 7.1M
the 29 Nov 2024 report24 earlier reportsnormal: 4.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

17 Mar 2020confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

AnaptysBio (ANAB): saw 34 13F filers open a new position in the quarter ended 31 Dec 2019, 2.0× the same quarter last year; it also had 6.0M shares sold short in the 13 Mar 2020 report, 1.8× the same report last year; and it reported revenue of $15.0M for the quarter ended 31 Mar 2020, against none in the same quarter last year. Three unrelated kinds of activity within 84 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2020
  • Short interest and volume: Short interest spike, became public on 11 Mar 2020
  • Short interest and volume: Short interest spike, became public on 25 Mar 2020
  • Short interest and volume: Short interest spike, became public on 10 Apr 2020
  • Short interest and volume: Short interest spike, became public on 25 Apr 2020
  • Financials: Quarterly revenue change, became public on 12 May 2020
2017-12-31: 482018-03-31: 332018-06-30: 202018-09-30: 222018-12-31: 172019-03-31: 212019-06-30: 212019-09-30: 152019-12-31: 34
The quarter ended 31 Dec 2019 against the 8 quarters before it. this quarterearliernormal: 21
See the evidence (6 changes)

Institutional holdings: Many funds opening a new position became public on 14 Feb 2020

AnaptysBio saw 34 13F filers open a new position in the quarter ended 31 Dec 2019, 2.0× the same quarter last year.

This period
34 (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
21
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.5
Same quarter last year
17
History used
1,005 days
2017-12-31: 482018-03-31: 332018-06-30: 202018-09-30: 222018-12-31: 172019-03-31: 212019-06-30: 212019-09-30: 152019-12-31: 34
the quarter ended 31 Dec 20198 earlier quartersnormal: 21

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Mar 2020

AnaptysBio had 5.6M shares sold short in the 28 Feb 2020 report, 1.8× the same report last year.

This period
5.6M (the 28 Feb 2020 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
317K
How far from its usual level
+4.2
Same report last year
3.2M
History used
791 days
2019-02-28: 3.2M2019-03-15: 3.4M2019-03-29: 3.4M2019-04-15: 3.7M2019-04-30: 3.8M2019-05-15: 3.9M2019-05-31: 3.7M2019-06-14: 3.5M2019-06-28: 4.0M2019-07-15: 4.2M2019-07-31: 4.2M2019-08-15: 4.0M2019-08-30: 3.6M2019-09-13: 3.6M2019-09-30: 3.4M2019-10-15: 3.1M2019-10-31: 3.2M2019-11-15: 3.2M2019-11-29: 3.3M2019-12-13: 3.5M2019-12-31: 4.0M2020-01-15: 4.4M2020-01-31: 5.0M2020-02-14: 5.2M2020-02-28: 5.6M
the 28 Feb 2020 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2020

AnaptysBio had 6.0M shares sold short in the 13 Mar 2020 report, 1.8× the same report last year.

This period
6.0M (the 13 Mar 2020 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
281K
How far from its usual level
+5.5
Same report last year
3.4M
History used
805 days
2019-03-15: 3.4M2019-03-29: 3.4M2019-04-15: 3.7M2019-04-30: 3.8M2019-05-15: 3.9M2019-05-31: 3.7M2019-06-14: 3.5M2019-06-28: 4.0M2019-07-15: 4.2M2019-07-31: 4.2M2019-08-15: 4.0M2019-08-30: 3.6M2019-09-13: 3.6M2019-09-30: 3.4M2019-10-15: 3.1M2019-10-31: 3.2M2019-11-15: 3.2M2019-11-29: 3.3M2019-12-13: 3.5M2019-12-31: 4.0M2020-01-15: 4.4M2020-01-31: 5.0M2020-02-14: 5.2M2020-02-28: 5.6M2020-03-13: 6.0M
the 13 Mar 2020 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Apr 2020

AnaptysBio had 6.2M shares sold short in the 31 Mar 2020 report, 1.8× the same report last year.

This period
6.2M (the 31 Mar 2020 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
360K
How far from its usual level
+4.6
Same report last year
3.4M
History used
823 days
2019-03-29: 3.4M2019-04-15: 3.7M2019-04-30: 3.8M2019-05-15: 3.9M2019-05-31: 3.7M2019-06-14: 3.5M2019-06-28: 4.0M2019-07-15: 4.2M2019-07-31: 4.2M2019-08-15: 4.0M2019-08-30: 3.6M2019-09-13: 3.6M2019-09-30: 3.4M2019-10-15: 3.1M2019-10-31: 3.2M2019-11-15: 3.2M2019-11-29: 3.3M2019-12-13: 3.5M2019-12-31: 4.0M2020-01-15: 4.4M2020-01-31: 5.0M2020-02-14: 5.2M2020-02-28: 5.6M2020-03-13: 6.0M2020-03-31: 6.2M
the 31 Mar 2020 report24 earlier reportsnormal: 3.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2020

AnaptysBio had 6.2M shares sold short in the 15 Apr 2020 report, 1.7× the same report last year.

This period
6.2M (the 15 Apr 2020 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
384K
How far from its usual level
+4.2
Same report last year
3.7M
History used
838 days
2019-04-15: 3.7M2019-04-30: 3.8M2019-05-15: 3.9M2019-05-31: 3.7M2019-06-14: 3.5M2019-06-28: 4.0M2019-07-15: 4.2M2019-07-31: 4.2M2019-08-15: 4.0M2019-08-30: 3.6M2019-09-13: 3.6M2019-09-30: 3.4M2019-10-15: 3.1M2019-10-31: 3.2M2019-11-15: 3.2M2019-11-29: 3.3M2019-12-13: 3.5M2019-12-31: 4.0M2020-01-15: 4.4M2020-01-31: 5.0M2020-02-14: 5.2M2020-02-28: 5.6M2020-03-13: 6.0M2020-03-31: 6.2M2020-04-15: 6.2M
the 15 Apr 2020 report24 earlier reportsnormal: 3.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 12 May 2020

AnaptysBio reported revenue of $15.0M for the quarter ended 31 Mar 2020, against none in the same quarter last year.

This period
$15.0M (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+15.0
Same quarter last year
$0
History used
1,461 days
2018-03-31: $02018-06-30: $02018-09-30: $5.0M2018-12-31: $02019-03-31: $02019-06-30: $5.0M2019-09-30: $02019-12-31: $3.0M2020-03-31: $15.0M
the quarter ended 31 Mar 20208 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 18 Nov 2026Insiders record

    EcoR1 Capital, LLC (director) and 1 other(s) bought 374,580 shares of ANAB ($17.2M)

  2. 11 May 2026Filings record

    Director or officer change

  3. 20 Apr 2026Filings record

    Director or officer change

  4. 20 Apr 2026Filings record

    Completed an acquisition or asset sale

  5. 27 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 27 Mar 2026Filings record

    Director or officer change

  7. 27 Mar 2026Filings record

    A major agreement ended

  8. 5 Mar 2026Financials change

    reported revenue of $108.2M for the quarter ended 31 Dec 2025, 2.5× the same quarter last year.

    Same quarter last year: $43.1M; its normal quarter is $25.0M.

    See the evidence
    This period
    $108.2M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $25.0M
    Typical spread (median absolute deviation)
    $15.0M
    How far from its usual level
    +3.7
    Same quarter last year
    $43.1M
    History used
    3,562 days
    2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M2024-12-31: $43.1M2025-03-31: $27.8M2025-06-30: $22.3M2025-09-30: $76.3M2025-12-31: $108.2M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $25.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  9. 6 Nov 2025Financials change

    reported revenue of $76.3M for the quarter ended 30 Sep 2025, 2.5× the same quarter last year.

    Same quarter last year: $30.0M; its normal quarter is $16.6M.

    See the evidence
    This period
    $76.3M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $16.6M
    Typical spread (median absolute deviation)
    $10.3M
    How far from its usual level
    +3.9
    Same quarter last year
    $30.0M
    History used
    3,470 days
    2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M2024-12-31: $43.1M2025-03-31: $27.8M2025-06-30: $22.3M2025-09-30: $76.3M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $16.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  10. 15 May 2025Institutional holdings change

    saw 43 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 14.5.

    See the evidence
    This period
    43 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    14.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +5.5
    Same quarter last year
    23
    History used
    2,922 days
    2023-03-31: 132023-06-30: 132023-09-30: 102023-12-31: 122024-03-31: 232024-06-30: 222024-09-30: 322024-12-31: 162025-03-31: 43
    the quarter ended 31 Mar 20258 earlier quartersnormal: 14.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 4 Mar 2025Financials change

    reported revenue of $43.1M for the quarter ended 31 Dec 2024, 4.8× the same quarter last year.

    Same quarter last year: $9.0M; its normal quarter is $5.3M.

    See the evidence
    This period
    $43.1M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $5.3M
    Typical spread (median absolute deviation)
    $3.8M
    How far from its usual level
    +6.7
    Same quarter last year
    $9.0M
    History used
    3,197 days
    2022-09-30: $1.3M2023-03-31: $1.4M2023-06-30: $3.5M2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M2024-12-31: $43.1M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $5.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 3 Jan 2025Insiders record

    EcoR1 Capital, LLC (director) and 1 other(s) bought 85,098 shares of ANAB ($1.1M) (dated 2 Jan 2025)

  13. 11 Dec 2024Short interest and volume change

    had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year.

    Same report last year: 5.0M; its normal report is 4.7M.

    See the evidence
    This period
    7.1M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    4.7M
    Typical spread (median absolute deviation)
    436K
    How far from its usual level
    +3.7
    Same report last year
    5.0M
    History used
    2,527 days
    2023-11-30: 5.0M2023-12-15: 4.5M2023-12-29: 4.5M2024-01-12: 4.5M2024-01-31: 5.1M2024-02-15: 4.5M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 4.3M2024-04-15: 4.3M2024-04-30: 4.4M2024-05-15: 4.4M2024-05-31: 4.5M2024-06-14: 4.6M2024-06-28: 4.9M2024-07-15: 5.2M2024-07-31: 5.7M2024-08-15: 5.6M2024-08-30: 5.6M2024-09-13: 5.8M2024-09-30: 6.0M2024-10-15: 6.0M2024-10-31: 6.2M2024-11-15: 6.7M2024-11-29: 7.1M
    the 29 Nov 2024 report24 earlier reportsnormal: 4.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 19 Nov 2024several at once

    reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year; it also saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year; and it had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year. Three unrelated kinds of activity within 35 days.

    See the evidence (3 changes)

    Financials: Quarterly revenue change became public on 12 Nov 2024

    AnaptysBio reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year.

    This period
    $30.0M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $3.4M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    +8.4
    Same quarter last year
    $3.3M
    History used
    3,105 days
    2022-06-30: $1.2M2022-09-30: $1.3M2023-03-31: $1.4M2023-06-30: $3.5M2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $3.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

    AnaptysBio saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year.

    This period
    32 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    12.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +6.5
    Same quarter last year
    10
    History used
    2,740 days
    2022-09-30: 112022-12-31: 102023-03-31: 132023-06-30: 132023-09-30: 102023-12-31: 122024-03-31: 232024-06-30: 222024-09-30: 32
    the quarter ended 30 Sep 20248 earlier quartersnormal: 12.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 11 Dec 2024

    AnaptysBio had 7.1M shares sold short in the 29 Nov 2024 report, 1.4× the same report last year.

    This period
    7.1M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    4.7M
    Typical spread (median absolute deviation)
    436K
    How far from its usual level
    +3.7
    Same report last year
    5.0M
    History used
    2,527 days
    2023-11-30: 5.0M2023-12-15: 4.5M2023-12-29: 4.5M2024-01-12: 4.5M2024-01-31: 5.1M2024-02-15: 4.5M2024-02-29: 4.2M2024-03-15: 4.1M2024-03-28: 4.3M2024-04-15: 4.3M2024-04-30: 4.4M2024-05-15: 4.4M2024-05-31: 4.5M2024-06-14: 4.6M2024-06-28: 4.9M2024-07-15: 5.2M2024-07-31: 5.7M2024-08-15: 5.6M2024-08-30: 5.6M2024-09-13: 5.8M2024-09-30: 6.0M2024-10-15: 6.0M2024-10-31: 6.2M2024-11-15: 6.7M2024-11-29: 7.1M
    the 29 Nov 2024 report24 earlier reportsnormal: 4.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 14 Nov 2024Institutional holdings change

    saw 32 13F filers open a new position in the quarter ended 30 Sep 2024, 3.2× the same quarter last year.

    Same quarter last year: 10; its normal quarter is 12.5.

    See the evidence
    This period
    32 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    12.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +6.5
    Same quarter last year
    10
    History used
    2,740 days
    2022-09-30: 112022-12-31: 102023-03-31: 132023-06-30: 132023-09-30: 102023-12-31: 122024-03-31: 232024-06-30: 222024-09-30: 32
    the quarter ended 30 Sep 20248 earlier quartersnormal: 12.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 12 Nov 2024Financials change

    reported revenue of $30.0M for the quarter ended 30 Sep 2024, 9.0× the same quarter last year.

    Same quarter last year: $3.3M; its normal quarter is $3.4M.

    See the evidence
    This period
    $30.0M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $3.4M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    +8.4
    Same quarter last year
    $3.3M
    History used
    3,105 days
    2022-06-30: $1.2M2022-09-30: $1.3M2023-03-31: $1.4M2023-06-30: $3.5M2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M2024-09-30: $30.0M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $3.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 17 Aug 2024Insiders record

    EcoR1 Capital, LLC (ten percent owner) bought 273,972 shares of ANAB ($10.0M) (dated 16 Aug 2024)

  18. 6 Aug 2024Financials change

    reported revenue of $11.0M for the quarter ended 30 Jun 2024, 3.2× the same quarter last year.

    Same quarter last year: $3.5M; its normal quarter is $2.3M.

    See the evidence
    This period
    $11.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $2.3M
    Typical spread (median absolute deviation)
    $1.1M
    How far from its usual level
    +5.2
    Same quarter last year
    $3.5M
    History used
    3,013 days
    2022-03-31: $970K2022-06-30: $1.2M2022-09-30: $1.3M2023-03-31: $1.4M2023-06-30: $3.5M2023-09-30: $3.3M2023-12-31: $9.0M2024-03-31: $7.2M2024-06-30: $11.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $2.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  19. 15 May 2024Institutional holdings change

    saw 23 13F filers open a new position in the quarter ended 31 Mar 2024, 1.8× the same quarter last year.

    Same quarter last year: 13; its normal quarter is 12.5.

    See the evidence
    This period
    23 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    12.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +3.5
    Same quarter last year
    13
    History used
    2,557 days
    2022-03-31: 142022-06-30: 152022-09-30: 112022-12-31: 102023-03-31: 132023-06-30: 132023-09-30: 102023-12-31: 122024-03-31: 23
    the quarter ended 31 Mar 20248 earlier quartersnormal: 12.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  20. 18 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 18 Sep 2023Filings record

    Director or officer change

  22. 6 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 6 Apr 2023Filings record

    Director or officer change

  24. 26 Oct 2022Short interest and volume change

    had 5.5M shares sold short in the 14 Oct 2022 report, 2.2× the same report last year.

    Same report last year: 2.5M; its normal report is 2.7M.

    See the evidence
    This period
    5.5M (the 14 Oct 2022 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    390K
    How far from its usual level
    +4.9
    Same report last year
    2.5M
    History used
    1,750 days
    2021-09-30: 2.6M2021-10-15: 2.5M2021-10-29: 2.4M2021-11-15: 2.3M2021-11-30: 2.3M2021-12-15: 2.3M2022-01-14: 2.2M2022-01-31: 2.3M2022-02-15: 2.3M2022-02-28: 2.5M2022-03-15: 2.8M2022-03-31: 2.4M2022-04-14: 2.4M2022-04-29: 2.9M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 3.7M2022-06-30: 3.9M2022-07-15: 4.0M2022-07-29: 4.5M2022-08-15: 4.4M2022-08-31: 5.2M2022-09-15: 5.4M2022-09-30: 5.6M2022-10-14: 5.5M
    the 14 Oct 2022 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 13 Oct 2022Short interest and volume change

    had 5.6M shares sold short in the 30 Sep 2022 report, 2.2× the same report last year.

    Same report last year: 2.6M; its normal report is 2.7M.

    See the evidence
    This period
    5.6M (the 30 Sep 2022 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    379K
    How far from its usual level
    +5.2
    Same report last year
    2.6M
    History used
    1,736 days
    2021-09-15: 2.8M2021-09-30: 2.6M2021-10-15: 2.5M2021-10-29: 2.4M2021-11-15: 2.3M2021-11-30: 2.3M2021-12-15: 2.3M2022-01-14: 2.2M2022-01-31: 2.3M2022-02-15: 2.3M2022-02-28: 2.5M2022-03-15: 2.8M2022-03-31: 2.4M2022-04-14: 2.4M2022-04-29: 2.9M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 3.7M2022-06-30: 3.9M2022-07-15: 4.0M2022-07-29: 4.5M2022-08-15: 4.4M2022-08-31: 5.2M2022-09-15: 5.4M2022-09-30: 5.6M
    the 30 Sep 2022 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 27 Sep 2022Short interest and volume change

    had 5.4M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.

    Same report last year: 2.8M; its normal report is 2.7M.

    See the evidence
    This period
    5.4M (the 15 Sep 2022 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    360K
    How far from its usual level
    +5.1
    Same report last year
    2.8M
    History used
    1,721 days
    2021-08-31: 2.9M2021-09-15: 2.8M2021-09-30: 2.6M2021-10-15: 2.5M2021-10-29: 2.4M2021-11-15: 2.3M2021-11-30: 2.3M2021-12-15: 2.3M2022-01-14: 2.2M2022-01-31: 2.3M2022-02-15: 2.3M2022-02-28: 2.5M2022-03-15: 2.8M2022-03-31: 2.4M2022-04-14: 2.4M2022-04-29: 2.9M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 3.7M2022-06-30: 3.9M2022-07-15: 4.0M2022-07-29: 4.5M2022-08-15: 4.4M2022-08-31: 5.2M2022-09-15: 5.4M
    the 15 Sep 2022 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 13 Sep 2022Short interest and volume change

    had 5.2M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.

    Same report last year: 2.9M; its normal report is 2.7M.

    See the evidence
    This period
    5.2M (the 31 Aug 2022 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    340K
    How far from its usual level
    +5.0
    Same report last year
    2.9M
    History used
    1,706 days
    2021-08-13: 2.9M2021-08-31: 2.9M2021-09-15: 2.8M2021-09-30: 2.6M2021-10-15: 2.5M2021-10-29: 2.4M2021-11-15: 2.3M2021-11-30: 2.3M2021-12-15: 2.3M2022-01-14: 2.2M2022-01-31: 2.3M2022-02-15: 2.3M2022-02-28: 2.5M2022-03-15: 2.8M2022-03-31: 2.4M2022-04-14: 2.4M2022-04-29: 2.9M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 3.7M2022-06-30: 3.9M2022-07-15: 4.0M2022-07-29: 4.5M2022-08-15: 4.4M2022-08-31: 5.2M
    the 31 Aug 2022 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 25 Aug 2022Short interest and volume change

    had 4.4M shares sold short in the 15 Aug 2022 report, 1.5× the same report last year.

    Same report last year: 2.9M; its normal report is 2.7M.

    See the evidence
    This period
    4.4M (the 15 Aug 2022 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    321K
    How far from its usual level
    +3.6
    Same report last year
    2.9M
    History used
    1,690 days
    2021-07-30: 2.9M2021-08-13: 2.9M2021-08-31: 2.9M2021-09-15: 2.8M2021-09-30: 2.6M2021-10-15: 2.5M2021-10-29: 2.4M2021-11-15: 2.3M2021-11-30: 2.3M2021-12-15: 2.3M2022-01-14: 2.2M2022-01-31: 2.3M2022-02-15: 2.3M2022-02-28: 2.5M2022-03-15: 2.8M2022-03-31: 2.4M2022-04-14: 2.4M2022-04-29: 2.9M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 3.7M2022-06-30: 3.9M2022-07-15: 4.0M2022-07-29: 4.5M2022-08-15: 4.4M
    the 15 Aug 2022 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 Aug 2022Short interest and volume change

    had 4.5M shares sold short in the 29 Jul 2022 report, 1.5× the same report last year.

    Same report last year: 2.9M; its normal report is 2.7M.

    See the evidence
    This period
    4.5M (the 29 Jul 2022 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    321K
    How far from its usual level
    +3.8
    Same report last year
    2.9M
    History used
    1,673 days
    2021-07-15: 3.1M2021-07-30: 2.9M2021-08-13: 2.9M2021-08-31: 2.9M2021-09-15: 2.8M2021-09-30: 2.6M2021-10-15: 2.5M2021-10-29: 2.4M2021-11-15: 2.3M2021-11-30: 2.3M2021-12-15: 2.3M2022-01-14: 2.2M2022-01-31: 2.3M2022-02-15: 2.3M2022-02-28: 2.5M2022-03-15: 2.8M2022-03-31: 2.4M2022-04-14: 2.4M2022-04-29: 2.9M2022-05-13: 3.7M2022-05-31: 3.3M2022-06-15: 3.7M2022-06-30: 3.9M2022-07-15: 4.0M2022-07-29: 4.5M
    the 29 Jul 2022 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 10 May 2022Insiders record

    EcoR1 Capital, LLC (ten percent owner) and 1 other(s) bought 668,237 shares of ANAB ($14.5M) (dated 9 May 2022)

  31. 29 Apr 2022Filings record

    Director or officer change

  32. 21 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 21 Mar 2022Filings record

    Director or officer change

  34. 1 Dec 2021Filings record

    Completed an acquisition or asset sale

  35. 29 Nov 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 29 Nov 2021Filings record

    Director or officer change

  37. 10 Aug 2021Financials change

    reported revenue of $30.0M for the quarter ended 30 Jun 2021, against none in the same quarter last year.

    See the evidence
    This period
    $30.0M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $4.0M
    Typical spread (median absolute deviation)
    $4.0M
    How far from its usual level
    +4.4
    Same quarter last year
    $0
    History used
    1,917 days
    2019-06-30: $5.0M2019-09-30: $02019-12-31: $3.0M2020-03-31: $15.0M2020-06-30: $02020-09-30: $02020-12-31: $60.0M2021-03-31: $11.2M2021-06-30: $30.0M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $4.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  38. 5 May 2021Insiders record

    NODELMAN OLEG (director) and 1 other(s) bought 221,500 shares of ANAB ($5.1M) (dated 4 May 2021)

  39. 28 Apr 2021Insiders record

    NODELMAN OLEG (director) and 1 other(s) bought 147,300 shares of ANAB ($3.5M) (dated 27 Apr 2021)

  40. 12 Apr 2021Filings record

    Director or officer change

Showing the newest 40 of 85 entries; narrow the window or the kind of data to see older ones.

Not listed: 179 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001370053
Ticker
ANAB
Domain
anaptysbio.com
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Name
AnaptysBio, Inc., ANAPTYS BIOSCIENCES INC
Uei
MSWSM1BGJNZ6
  • SEC Form 13F institutional holdings351 data points31 Mar 2017 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)139 records16 Feb 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)575 data points31 Dec 2014 to 9 Nov 2026
  • SEC Form 4 insider transactions88 records, 236 data points31 Jan 2017 to 18 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 21 data points17 Jun 2010 to 19 Mar 2015